Thought Nina presented very well. Not much info given on the offers, however she stressed Dimerix "had offers on the table from global players"
I also liked the comparison with Neuron and their licensing deal. It really shows the sort of figures we are looking at. And there are enough parallels here.
To say she was only given 8 minutes, I feel like she did well making it known there were near-term catalysts and how commercially lucrative this opportunity is
Ann: FSGS Study, Partnering & Commercialisation Investor Briefing, page-22
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $209.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.5¢ | 36.5¢ | $579.4K | 1.548M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 91570 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 7922 | 2 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| DXB (ASX) Chart |